The One GLP-1 Rule That Is Identical on Every Label — and It Asks About Your Relatives

GLP-1 labels disagree about a lot. Missed-dose windows run from three days to five, or none at all. Starting doses differ, titration schedules differ, and two brands of the same molecule can describe the same decision from opposite directions.

One instruction does not vary. It appears across eight products from four manufacturers as the same sentence every time, down to the punctuation.

Ozempic, label revised 10 June 2026:

"Do not use OZEMPIC if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC), or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)."

Mounjaro, revised 6 May 2026:

"Do not use MOUNJARO if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC), or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)."

Saxenda, revised 15 June 2026. Trulicity, revised 10 August 2026. Bydureon BCise. Same sentence, own brand name inserted.

Read the subject of that sentence again

*"if you or any of your family."*

Almost every contraindication in medicine is about you — your kidneys, your pregnancy, your other prescriptions. This one asks about people who are not in the room, about a cancer most of them have never heard of, possibly a generation back.

It sits in the boxed warning rather than among the ordinary cautions, which is a different tier from the side effects most people actually encounter.

Medullary thyroid carcinoma is rare, and the inherited form travels with MEN 2. That is why family history is doing real work here rather than being an abundance of caution: if it runs in the family, it may be in the genes.

Which produces a question worth sitting with before an intake appointment. Not "has anyone in my family had thyroid cancer" — most people would remember that — but do you know which type? Papillary and follicular thyroid cancers are far more common and are not what this sentence is about. "Thyroid cancer, I think, on my mother's side" does not answer it either way.

Why the wording is identical everywhere

These sentences come from the boxed warning, the most serious category the FDA applies. The finding behind it is from rodent studies: these drugs caused thyroid C-cell tumours in rats and mice at clinically relevant exposures. Whether that translates to humans has not been determined, which is precisely why the labels contraindicate rather than merely caution — and why the language is standardised across the class rather than negotiated per product.

The practical consequence: switching brands does not switch this rule. Nearly everything else about a regimen can change when you move between GLP-1s. This does not.

The one label where the wording differs, and it is not about thyroid

The Rybelsus label, revised 20 May 2026, carries the same sentence with an extra name in it:

"Do not use RYBELSUS or OZEMPIC tablets if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC), or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)."

Rybelsus or Ozempic tablets. Novo Nordisk retired the Rybelsus brand in the United States in May 2026 and moved the same molecule to Ozempic tablets. The label carries both names through the transition — which means a pharmacy handing over a box labelled differently from the prescription is not necessarily an error.

That is a rename, not a withdrawal, and the distinction matters: the product still exists. Compare Bydureon BCise and Byetta, which AstraZeneca discontinued in October 2024, and Victoza, discontinued in April 2024. Those are genuinely gone.

What to do with this

Find out the type, not just the fact. If thyroid cancer is anywhere in the family, the question at the appointment is whether it was medullary. If nobody knows, say that rather than guessing in either direction.

Ask about MEN 2 separately. It is a distinct condition, named separately in the contraindication.

Do not assume switching brands resets the question. It is the same sentence on every label in the class.

Check the revision date on anything you read, including this. Trulicity's label is August 2026, Rybelsus's May 2026. An article written a year ago describes labels that have since been revised.

Where this comes from

Every quotation is from the manufacturer's own Structured Product Label on DailyMed, the National Library of Medicine's repository. We use the manufacturer's label rather than a repackager's copy — a name search returns repackagers first for most of these drugs, and their versions can lag.

Which products have been discontinued and which were renamed is kept current and dated.

This is information, not medical advice. The contraindication is a decision for you and your prescriber — what the label gives you is the exact question to arrive with.